混合前药物纳米组件用于缺氧触发的免疫性化疗和免疫调节
Beiyuan Zhang1, Chao Qin1, Xue Wang1
1Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
概括
这项研究引入了一种双原药纳米组件 (CPPA),该组件在缺氧下向瘤. 通过触发细胞死亡和增强免疫反应,抑制癌症进展和转移,CPPA增强化疗和免疫疗.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 瘤缺氧驱动癌症的进展,转移和治疗耐药性.
- 低氧激活的前期药物显示有前途,但面临有效性挑战.
- 克服瘤免疫逃避对于有效的癌症治疗至关重要.
研究的目的:
- 开发一种双原药纳米组件 (CPPA),用于增强瘤向化疗和免疫疗法.
- 为了利用缺氧触发的药物释放和STAT3抑制来改善癌症治疗.
- 为了应对瘤缺氧,免疫逃避和药物耐药性的挑战.
主要方法:
- 开发一种双原药纳米组件 (CPPA),结合坎普托素 (CPT) 和STAT3反感性寡核酸 (ASO) 原药.
- CPPA的自我组装成纳米细胞,用于治疗剂的联合递送.
- 在小鼠乳腺癌模型中评估CPPA疗效,评估瘤细胞杀死,免疫细胞透和微环境调节.
主要成果:
- 在小鼠乳腺癌模型中,CPPA表现出卓越的治疗效果.
- 低氧触发的CPT释放诱导免疫细胞死亡 (ICD).
- 通过ASO抑制STAT3,增强了抗瘤免疫反应,调节了瘤微环境,逆转了耐药性,并抑制了转移.
结论:
- 通过向瘤缺氧和免疫规避,CPPA是增强癌症免疫疗法的有希望的策略.
- 双原药纳米组件有效地抑制了瘤的进展和转移.
- 这种方法为复杂的癌症挑战提供了一个新的治疗途径.
相关概念视频
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
01:27Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472